Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2024)
Historic Return on Capital Employed for Denali Therapeutics (DNLI) over the last 7 years, with Q4 2024 value amounting to 0.37%.
- Denali Therapeutics' Return on Capital Employed fell 2000.0% to 0.37% in Q4 2024 from the same period last year, while for Dec 2024 it was 0.37%, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of 0.42% for FY2024, which is 2600.0% down from last year.
- Denali Therapeutics' Return on Capital Employed amounted to 0.37% in Q4 2024, which was down 2000.0% from 0.35% recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' Return on Capital Employed registered a high of 0.05% during Q4 2020, and its lowest value of 0.4% during Q1 2020.
- For the 5-year period, Denali Therapeutics' Return on Capital Employed averaged around 0.23%, with its median value being 0.29% (2022).
- In the last 5 years, Denali Therapeutics' Return on Capital Employed surged by 4500bps in 2020 and then crashed by -3700bps in 2022.
- Over the past 5 years, Denali Therapeutics' Return on Capital Employed (Quarter) stood at 0.05% in 2020, then plummeted by -669bps to 0.28% in 2021, then fell by -23bps to 0.35% in 2022, then surged by 49bps to 0.18% in 2023, then plummeted by -111bps to 0.37% in 2024.
- Its Return on Capital Employed was 0.37% in Q4 2024, compared to 0.35% in Q3 2024 and 0.33% in Q2 2024.